Actively Recruiting
Using Glialia for Treating Persistent Perceptual Postural Dizziness
Led by I.R.C.C.S. Fondazione Santa Lucia · Updated on 2025-11-20
30
Participants Needed
1
Research Sites
94 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This pilot study will involve 30 participants recruited from the Santa Lucia Foundation IRCCS, including 20 patients diagnosed with Persistent Perceptual Postural Dizziness (PPPD), and might or might not have previously contracted Sars Cov2 infection. They who will be randomly assigned to receive either the Glialia supplement or placebo. Additionally, 10 control participants who have recovered from COVID-19 will receive Glialia to help assess the influence of previous COVID-19 infection on neuroinflammation levels. The study aims to compare baseline neuroinflammation levels between PPPD patients and controls, measure changes in neuroinflammation in all groups after treatment and to determine if the reduction in neuroinflammation is more significant in the Glialia group compared to the placebo group. The trial will be conducted in a triple-blind manner, ensuring that neither participants nor researchers know the treatment assignments. Each participant will receive sachets to be taken daily for 60 days, with the study providing both the Glialia supplement and placebo at no cost.
CONDITIONS
Official Title
Using Glialia for Treating Persistent Perceptual Postural Dizziness
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 65 years
- Diagnosis of Persistent Perceptual Postural Dizziness (PPPD) for PPPD groups
- Recovery from COVID-19 infection or absence of previous infection for PPPD groups
- Previous COVID-19 infection for control group
You will not qualify if you...
- Presence of other neurological and ear-related disorders besides PPPD for PPPD groups
- Pregnancy
- Presence of neurological and ear-related disorders for control group
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fondazione Santa Lucia IRCCS
Rome, RM, Italy, 00142
Actively Recruiting
Research Team
I
Iole Indovina, PhD
CONTACT
D
Diego Piatti, PT
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here